Facioscapulohumeral Muscular Dystrophy Market Poised for Transformative Growth as Gene-Targeted Therapies Advance Toward Regulatory Submissions
Key Insights
The FSHD market across the 7MM is projected to grow substantially by 2036, driven by the anticipated launch of disease-modifying therapies and increasing diagnosis rates.
In 2025, the United States accounted for approximately 45% of total diagnosed FSHD cases across the 7MM, with nearly 16,000 FSHD1 and 800 FSHD2 cases.
Novartis completed its acquisition of Avidity Biosciences in January 2026, gaining access to Delpacibart braxlosiran, with global regulatory submissions anticipated in 2028.
The Facioscapulohumeral Muscular Dystrophy (search) (FSHD) treatment landscape is on the cusp of a fundamental transformation, with multiple disease-modifying therapies advancing through clinical development and the market projected to witness significant growth by 2036, according to a comprehensive report from DelveInsight. Currently, no disease-modifying therapy has received regulatory approval for FSHD, leaving patients reliant on supportive care, rehabilitation, and pain management.
The seven major markets (7MM) — encompassing the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan — are expected to see substantial market expansion during the 2026–2036 forecast period, fueled by the anticipated launch of emerging therapies and improving diagnostic rates.
Epidemiology and Disease Burden
FSHD is one of the most common inherited adult-onset muscular dystrophies, characterized by progressive weakness and wasting of the facial, shoulder-girdle, and upper-arm muscles. The disorder is caused by abnormal activation of the DUX4 (search) gene, resulting from genetic alterations involving the D4Z4 repeat region on chromosome 4. FSHD is classified into Type 1 (FSHD1) and Type 2 (FSHD2), with FSHD1 accounting for approximately 95% of all cases, according to the FSHD Society.
In 2025, the United States accounted for approximately 45% of the total diagnosed FSHD cases across the 7MM. Specifically, there were nearly 16,000 cases of FSHD1 and approximately 800 cases of FSHD2 in the U.S. According to Sanson et al. (2022), the prevalence of FSHD is estimated at approximately 1 in 8,000 to 1 in 15,000 in the United States and around 1 in 20,000 in both Italy and the United Kingdom. The National Organization for Rare Disorders (NORD) (2020) notes that FSHD affects males and females in relatively equal numbers, with an estimated prevalence of 4–10 cases per 100,000 individuals.
A Pipeline Primed for Breakthroughs
The FSHD therapeutic pipeline has expanded considerably, with leading companies including Novartis, Roche, Chugai Pharmaceutical, Epicrispr Biotechnologies (search), Modalis Therapeutics, and Restem (search) developing innovative therapies designed to suppress DUX4 (search) expression, inhibit myostatin, and improve muscle strength and function.
Delpacibart braxlosiran (del-brax), an RNA-targeted therapy designed to suppress abnormal DUX4 (search) expression, represents one of the most advanced candidates. In January 2026, Novartis completed its acquisition of Avidity Biosciences, strengthening its neuromuscular disease pipeline and gaining access to del-brax. The Phase III FORTITUDE-3 trial is underway, with topline biomarker data expected in the second quarter of 2026 and global regulatory submissions anticipated in 2028.
GYM329/RO7204239/RG6237 (search), being developed by Roche and Chugai Pharmaceutical, targets myostatin inhibition to improve muscle strength. Meanwhile, Epicrispr Biotechnologies (search) announced in August 2025 the dosing of the first patient in its global first-in-human Phase I/II clinical trial evaluating EPI-321, an investigational gene-modulating therapy designed to silence DUX4 (search) expression through epigenetic modulation.
In December 2025, Restem (search) announced that the first patient had been dosed in the Phase I/IIa clinical study evaluating Restem-L in patients with FSHD, with the trial supported through a partnership with SOLVE FSHD.
Setbacks and Lessons Learned
The FSHD field has not been without setbacks. In September 2024, Fulcrum Therapeutics announced that the Phase III REACH trial evaluating losmapimod failed to meet its primary endpoint, leading the company to discontinue further development of the investigational therapy. This outcome underscores the challenges inherent in developing treatments for genetically complex neuromuscular disorders and highlights the importance of the diverse mechanistic approaches now advancing in the pipeline.
Market Drivers and Future Outlook
Key factors propelling the FSHD market include increasing disease awareness, improved availability of genetic testing, and enhanced understanding of the molecular basis of FSHD, all of which are facilitating earlier diagnosis and appropriate disease management. Additionally, growing investment from biotechnology and pharmaceutical companies, coupled with orphan drug incentives, strategic acquisitions, and advances in RNA-targeting and gene-editing technologies, is accelerating clinical development.
The current treatment landscape remains limited to supportive care, rehabilitation, pain management, and surgical interventions. As disease-modifying therapies progress toward potential regulatory approvals, the FSHD treatment paradigm stands to be fundamentally altered, addressing the substantial unmet medical needs of patients living with this progressive neuromuscular disorder.